The library will be closed between August 10, 2026 and August 16, 2026. During this period, it will be possible to upload publications, but all other services will be suspended.
Farkas, S.,
Nagy, K.,
Palkovits, M.,
Kovács, G. G.,
Jia, Z.,
Donohue, S.,
Pike, V.,
Halldin, C.,
Máthé, D.,
Harkány, T.,
Gulyás, B.,
Csiba, L.:
[125I]SD-7015 reveals fine modalities of CB1 cannabinoid receptor density in the prefrontal cortex during progression of Alzheimer's disease.
Neurochem. Int. 60 (3), 286-291, 2012.
Farkas, S.,
Molnár, S.,
Nagy, K.,
Hortobágyi, T.,
Csiba, L.:
Comparative in vivo and in vitro postmortem ultrasound assessment of intima-media thickness with additional histological analysis in human carotid arteries.
In: Perspectives in Medicine : New Trends in Neurosonology and Cerebral Hemodynamics - an Update Vol.1. Eds.: Eva Bartels, Susanne Bartels, Holger Poppert, Elsevier, Amsterdam, 170-176, 2012.
Farkas, S.,
Nagy, K.,
Jia, Z.,
Hortobágyi, T.,
Varrone, A.,
Halldin, C.,
Csiba, L.,
Gulyás, B.:
Signal transduction pathway activity compensates dopamine D2/D3 receptor density changes in Parkinson's disease: a preliminary comparative human brain receptor autoradiography study with [3H]raclopride and [35S]GTPgammaS.
Brain Res. 1453, 56-63, 2012.
Farkas, S.,
Nagy, K.,
Jia, Z.,
Harkány, T.,
Palkovits, M.,
Donohue, S.,
Pike, V.,
Halldin, C.,
Máthé, D.,
Csiba, L.,
Gulyás, B.:
The decrease of dopamine D2/D3 receptor densities in the putamen and nucleus caudatus goes parallel with maintained levels of CB1 cannabinoid receptors in Parkinson's disease: a preliminary autoradiographic study with the selective dopamine D2/D3 antagonist [3H]raclopride and the novel CB1 inverse agonist [125I]SD7015.
Brain Res. Bull. 87 (6), 504-510, 2012.
